Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw unusually-strong trading volume on Monday. Approximately 872,731 shares were traded during trading, a decline of 2% from the previous session’s volume of 893,689 shares. The stock last traded at $3.1750 and had previously closed at $3.16.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Guggenheim raised their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Finally, Truist Financial boosted their price target on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inventiva currently has an average rating of “Buy” and a consensus price target of $15.86.

Inventiva Stock Down 8.0%

The business has a 50 day simple moving average of $4.15 and a 200-day simple moving average of $4.52.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million for the quarter. Equities analysts predict that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Inventiva

Institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in Inventiva in the first quarter valued at $1,111,000. Persistent Asset Partners Ltd acquired a new stake in Inventiva during the fourth quarter worth about $603,000. Engineers Gate Manager LP raised its holdings in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. Finally, Platt Investment Counsel LLC purchased a new position in shares of Inventiva in the 3rd quarter worth about $45,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.